

Status of NICE TAs & HSTs on Gloucestershire Joint Formulary

No.	NICE TA (click to open link)	Compliant (Y/N)	Location on Formulary
TA1	<a href="#">Wisdom teeth - removal</a>	Not drug related	
TA2	<a href="#">Hip disease - replacement prostheses</a>	Not drug related	
TA10	<a href="#">Asthma (children under 5) - inhaler devices</a>	Y	N/A adult Formulary
TA17	<a href="#">Colorectal cancer - laparoscopic surgery</a>	Not drug related	
TA20	<a href="#">Motor neurone disease - riluzole (TA20)</a>	Y	Chapter 4
TA23	<a href="#">Brain cancer - temozolomide</a>	Y	No chapter 8
TA24	<a href="#">Wound care - debriding agents</a>	replaced by CG74 Surgical site infection	
TA25	<a href="#">Pancreatic cancer - gemcitabine</a>	Y	No chapter 8
TA26	<a href="#">Lung cancer - docetaxel, paclitaxel, gemcitabine and vinorelbine</a>	replaced by CG121	
TA29	<a href="#">Leukaemia (lymphocytic) - fludarabine</a>	Y	No chapter 8
TA30	<a href="#">Breast cancer - taxanes (review)</a>	replaced by CG81	
TA32	<a href="#">Multiple sclerosis - beta interferon and glatiramer acetate (TA32)</a>	Y	No chapter 8
TA34	<a href="#">Breast cancer - trastuzumab</a>	Y	No chapter 8
TA35	<a href="#">Arthritis (juvenile idiopathic) - etanercept</a>	replaced by TA373	
TA36	<a href="#">Rheumatoid arthritis - etanercept and infliximab</a>	replaced by TA130 and TA195	
TA38	<a href="#">Asthma (older children) - inhaler devices</a>	Y	N/A adult Formulary
TA40	<a href="#">Crohn's disease - infliximab</a>	replaced by TA187	
TA42	<a href="#">Growth hormone deficiency (children) - human growth hormone</a>	replaced by TA188	
TA43	<a href="#">Schizophrenia - atypical antipsychotics</a>	replaced by CG82	
TA44	<a href="#">Hip disease - metal on metal hip resurfacing</a>	replaced by TA304	
TA47	<a href="#">Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review) (TA47) (partially updated by CG94)</a>	Y	Chapter 2
TA48	<a href="#">Renal failure - home versus hospital haemodialysis</a>	Not drug related	
TA49	<a href="#">Central venous catheters - ultrasound locating devices</a>	Not drug related	
TA52	<a href="#">Myocardial infarction - thrombolysis</a>	Y	Chapter 2
TA53	<a href="#">Diabetes (types 1 and 2) - long acting insulin analogues (TA53)</a>	replaced by NG17	
TA54	<a href="#">Breast cancer - vinorelbine</a>	replaced by CG81	
TA55	<a href="#">Ovarian cancer - paclitaxel (review)</a>	Y	No chapter 8
TA59	<a href="#">Electroconvulsive therapy (ECT)</a>	Not drug related	
TA60	<a href="#">Diabetes (types 1 and 2) - patient education models</a>	Not drug related	
TA61	<a href="#">Colorectal cancer - capecitabine and tegafur uracil</a>	Y	No chapter 8
TA62	<a href="#">Breast cancer - capecitabine</a>	replaced by CG81	
TA64	<a href="#">Growth hormone deficiency (adults) - human growth hormone (TA64)</a>	Y	Chapter 6
TA65	<a href="#">Non-Hodgkin's lymphoma - rituximab</a>	Y	No chapter 8
TA67	<a href="#">Flu prevention - amantadine and oseltamivir</a>	replaced by TA158	
TA68	<a href="#">Macular degeneration (age-related) - photodynamic therapy</a>	Not drug related	
TA69	<a href="#">Cervical cancer - cervical screening (review)</a>	Not drug related	
TA70	<a href="#">Leukaemia (chronic myeloid) - imatinib</a>	Y	No chapter 8
TA71	<a href="#">Ischaemic heart disease - coronary artery stents</a>	Not drug related	
TA73	<a href="#">Angina and myocardial infarction - myocardial perfusion scintigraphy</a>	Not drug related	
TA74	<a href="#">Trauma - fluid replacement therapy</a>	Not drug related	
TA75	<a href="#">Hepatitis C - pegylated interferons, ribavirin and alfa interferon (TA75)</a>	Y	No chapter 8
TA76	<a href="#">Epilepsy (adults) - newer drugs</a>	replaced by CG137 Epilepsy	
TA77	<a href="#">Insomnia - newer hypnotic drugs (TA77)</a>	Y	Chapter 4
TA78	<a href="#">Menstrual bleeding - fluid-filled thermal balloon and microwave endometrial ablation</a>	Not drug related	

TA79	<a href="#">Epilepsy (children) - newer drugs</a>	replaced by CG137 Epilepsy	
TA80	<a href="#">Acute coronary syndromes - clopidogrel (TA80)</a>	Replaced by CG94	
TA81	<a href="#">Atopic dermatitis (eczema) - topical steroids (TA81)</a>	Y	Incorporated into local guidance
TA82	<a href="#">Atopic dermatitis (eczema) - pimecrolimus and tacrolimus (TA82)</a>	Y	Chapter 13
TA83	<a href="#">Hernia - laparoscopic surgery (review)</a>	Not drug related	
TA85	<a href="#">Renal transplantation - immuno-suppressive regimens (adults)</a>	Y	No chapter 8
TA86	<a href="#">Gastrointestinal stromal tumours - imatinib</a>	Y	No chapter 8
TA88	<a href="#">Bradycardia - dual chamber pacemakers</a>	Not drug related	
TA89	<a href="#">Cartilage injury - autologous chondrocyte implantation (ACI) (review)</a>	Not drug related	
TA90	<a href="#">Vascular disease - clopidogrel and dipyridamole</a>	replaced by TA210	
TA92	<a href="#">Tooth decay - HealOzone</a>	Not drug related	
TA94	<a href="#">Cardiovascular disease - statins (TA94)</a>	replaced by CG181	
TA95	<a href="#">Arrhythmia - implantable cardioverter defibrillators (ICDs) (review)</a>	Not drug related	
TA96	<a href="#">Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a (TA96)</a>	Y	No infections chapter
TA97	<a href="#">Depression and anxiety - computerised cognitive behavioural therapy (CCBT)</a>	Not drug related	
TA98	<a href="#">Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine (review) (TA98)</a>	Y	Chapter 4
TA99	<a href="#">Renal transplantation - immunosuppressive regimens for children and adolescents</a>	Y	No chapter 8
TA100	<a href="#">Colon cancer (adjuvant) - capecitabine and oxaliplatin</a>	Y	No chapter 8
TA101	<a href="#">Prostate cancer (hormone-refractory) - docetaxel</a>	Y	No chapter 8
TA102	<a href="#">Conduct disorder in children - parent-training/education programmes</a>	Not drug related	
TA103	<a href="#">Psoriasis - efalizumab and etanercept (TA103)</a>	Y	Chapter 13
TA104	<a href="#">Psoriatic arthritis - etanercept and infliximab</a>	replaced by TA199	
TA105	<a href="#">Colorectal cancer - laparoscopic surgery (review)</a>	Not drug related	
TA106	<a href="#">Hepatitis C - peginterferon alfa and ribavirin (TA106)</a>	Y	No chapter 8
TA107	<a href="#">Breast cancer (early) - trastuzumab</a>	replaced by CG80	
TA108	<a href="#">Breast cancer (early) - paclitaxel</a>	replaced by CG80	
TA109	<a href="#">Breast cancer (early) - docetaxel</a>	replaced by CG80	
TA110	<a href="#">Follicular lymphoma - rituximab</a>	replaced by TA243	
TA112	<a href="#">Breast cancer (early) - hormonal treatments</a>	Y	No chapter 8
TA113	<a href="#">Diabetes (type 1 and 2) - inhaled insulin</a>	Withdrawn	
TA114	<a href="#">Drug misuse - methadone and buprenorphine (TA114)</a>	Y	Chapter 4
TA115	<a href="#">Drug misuse - naltrexone (TA115)</a>	Y	Chapter 4
TA116	<a href="#">Breast cancer - gemcitabine</a>	Y	No chapter 8
TA117	<a href="#">Hyperparathyroidism - cinacalcet (TA117)</a>	Y	No chapter 9
TA118	<a href="#">Colorectal cancer (metastatic) - bevacizumab and cetuximab</a>	Y	No chapter 8
TA119	<a href="#">Leukaemia (lymphocytic) - fludarabine</a>	Negative recommendation	
TA120	<a href="#">Heart failure - cardiac resynchronisation</a>	Not drug related	
TA121	<a href="#">Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide</a>	Y	No chapter 8
TA122	<a href="#">Ischaemic stroke (acute) - alteplase (TA122)</a>	Replaced by TA264	
TA123	<a href="#">Smoking cessation - varenicline (TA123)</a>	Y	Chapter 4
TA124	<a href="#">Lung cancer (non-small-cell) - pemetrexed</a>	Y	No chapter 8
TA125	<a href="#">Psoriatic arthritis (moderate to severe) - adalimumab</a>	replaced by TA199	
TA126	<a href="#">Rheumatoid arthritis (refractory) - rituximab</a>	replaced by TA195	
TA127	<a href="#">Multiple sclerosis - natalizumab (TA127)</a>	Y	No chapter 8
TA128	<a href="#">Haemorrhoid - stapled haemorrhoidopexy</a>	Not drug related	
TA129	<a href="#">Multiple myeloma - bortezomib</a>	Y	No chapter 8
TA130	<a href="#">Rheumatoid arthritis - adalimumab, etanercept and infliximab (TA130)</a>	Replaced by TA375	

TA131	<a href="#">Asthma (in children) - corticosteroids</a>	Y	Incorporated into chapter
TA132	<a href="#">Hypercholesterolaemia - ezetimibe (TA132)</a>	Replaced by TA385	
TA133	<a href="#">Asthma (uncontrolled) - omalizumab (TA133)</a>	Replaced by TA278	
TA134	<a href="#">Psoriasis - infliximab (TA134)</a>	Y	Chapter 13
TA135	<a href="#">Mesothelioma - pemetrexed disodium</a>	Y	No chapter 8
TA136	<a href="#">Structural neuroimaging in first-episode psychosis</a>	Not drug related	
TA137	<a href="#">Lymphoma (follicular non-Hodgkin's) - rituximab</a>	Y	No chapter 8
TA138	<a href="#">Asthma (in adults) - corticosteroids (TA138)</a>	Y	Incorporated into chapter
TA139	<a href="#">Sleep apnoea - continuous positive airway pressure (CPAP)</a>	Not drug related	
TA140	<a href="#">Ulcerative colitis (subacute manifestations) - infliximab (TA140)</a>	Negative recommendation	
TA141	<a href="#">Rheumatoid arthritis (refractory) - abatacept</a>	replaced by TA195	
TA142	<a href="#">Anaemia (cancer-treatment induced) - erythropoietin (alpha and beta) and darbepoetin (TA142)</a>	replaced by TA323	
TA143	<a href="#">Ankylosing spondylitis - adalimumab, etanercept and infliximab (TA143)</a>	replaced by TA383	
TA145	<a href="#">Head and neck cancer - cetuximab</a>	Y	No chapter 8
TA146	<a href="#">Psoriasis - adalimumab (TA146)</a>	Y	Chapter 13
TA147	<a href="#">Breast cancer (advanced &amp; metastatic) - bevacizumab (withdrawn)</a>	replaced by TA214	
TA148	<a href="#">Lung cancer (non-small-cell) - bevacizumab (terminated appraisal)</a>	Terminated	
TA149	<a href="#">Glioma (recurrent) - carmustine implants (terminated appraisal)</a>	Terminated	
TA150	<a href="#">Colorectal cancer (metastatic) - cetuximab (terminated appraisal)</a>	Terminated	
TA151	<a href="#">Diabetes - insulin pump therapy (TA151)</a>	Y	Chapter 6
TA152	<a href="#">Coronary artery disease - drug-eluting stents</a>	Not drug related	
TA153	<a href="#">Hepatitis B - entecavir (TA153)</a>	Y	No infections chapter
TA154	<a href="#">Hepatitis B - telbivudine (TA154)</a>	Negative recommendation	
TA155	<a href="#">Macular degeneration (age-related) - ranibizumab and pegaptanib (TA155)</a>	Y	Chapter 11
TA156	<a href="#">Pregnancy (rhesus negative women) - routine anti-D (review)</a>	Not drug related	
TA157	<a href="#">Venous thromboembolism - dabigatran (TA157)</a>	Y	Chapter 2
TA158	<a href="#">Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir (TA158)</a>	Y	No infections chapter
TA159	<a href="#">Pain (chronic neuropathic or ischaemic) - spinal cord stimulation</a>	Not drug related	
TA160	<a href="#">Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women</a>	Y	Chapter 6
TA161	<a href="#">Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women</a>	Y	Chapter 6
TA162	<a href="#">Lung cancer (non-small-cell) - erlotinib</a>	replaced by TA374	
TA163	<a href="#">Ulcerative colitis (acute exacerbations) - infliximab (TA163)</a>	Y	Chapter 1
TA164	<a href="#">Hyperuricaemia - febuxostat (TA164)</a>	Y	Chapter 10
TA165	<a href="#">Organ preservation (renal) - machine perfusion and static storage</a>	Not drug related	
TA166	<a href="#">Hearing impairment - cochlear implants</a>	Not drug related	
TA167	<a href="#">Abdominal aortic aneurysm - endovascular stent-grafts</a>	Not drug related	
TA168	<a href="#">Influenza - zanamivir, amantadine and oseltamivir (review) (TA168)</a>	Y	No infections chapter
TA169	<a href="#">Renal cell carcinoma - sunitinib</a>	Y	No chapter 8
TA170	<a href="#">Venous thromboembolism - rivaroxaban (TA170)</a>	Y	Chapter 2
TA171	<a href="#">Multiple myeloma - lenalidomide</a>	Y	No chapter 8
TA172	<a href="#">Head and neck cancer (squamous cell carcinoma) - cetuximab</a>	Y	No chapter 8
TA173	<a href="#">Hepatitis B - tenofovir disoproxil fumarate (TA173)</a>	Y	No infections chapter
TA174	<a href="#">Leukaemia (chronic lymphocytic, first line) - rituximab</a>	Y	No chapter 8
TA175	<a href="#">Lung cancer (non-small-cell, second line) - gefitinib (terminated appraisal)</a>	Replaced by TA374	
TA176	<a href="#">Colorectal cancer (first line) - cetuximab</a>	Y	No chapter 8
TA177	<a href="#">Eczema (chronic) - alitretinoin (TA177)</a>	Y	Chapter 13

TA178	<a href="#">Renal cell carcinoma</a>	Negative recommendation	
TA179	<a href="#">Gastrointestinal stromal tumours - sunitinib</a>	Y	No chapter 8
TA180	<a href="#">Psoriasis - ustekinumab (TA180)</a>	Y	Chapter 13
TA181	<a href="#">Lung cancer (non-small-cell, first line treatment) - pemetrexed</a>	Y	No chapter 8
TA182	<a href="#">Acute coronary syndrome - prasugrel (TA182)</a>	replaced by TA317	
TA183	<a href="#">Cervical cancer (recurrent) - topotecan</a>	Y	No chapter 8
TA184	<a href="#">Lung cancer (small-cell) - topotecan</a>	Y	No chapter 8
TA185	<a href="#">Soft tissue sarcoma - trabectedin</a>	Y	No chapter 8
TA186	<a href="#">Rheumatoid arthritis - certolizumab pegol (TA186)</a>	replaced by TA375	
TA187	<a href="#">Crohn's disease - infliximab (review) and adalimumab (review of TA40) (TA187)</a>	Y	Chapter 1
TA188	<a href="#">Human growth hormone (somatropin) for the treatment of growth failure in children (review)</a>	Y	Chapter 6
TA189	<a href="#">Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)</a>	Negative recommendation	
TA190	<a href="#">Lung cancer (non-small-cell) - pemetrexed (maintenance)</a>	Y	No chapter 8
TA191	<a href="#">Gastric cancer (advanced) - capecitabine</a>	Y	No chapter 8
TA192	<a href="#">Lung cancer (non-small-cell, first line) - gefitinib</a>	Y	No chapter 8
TA193	<a href="#">Leukaemia (chronic lymphocytic, relapsed) - rituximab</a>	Y	No chapter 8
TA194	<a href="#">Bone loss (therapy-induced) in non-metastatic prostate cancer - denosumab (terminated appraisal)</a>	Terminated	
TA195	<a href="#">Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor (TA195)</a>	Y	Chapter 10
TA196	<a href="#">Gastrointestinal stromal tumours - imatinib (adjuvant)</a>	replaced by TA326	
TA197	<a href="#">Atrial fibrillation - dronedarone (TA197)</a>	Y	Chapter 2
TA198	<a href="#">Rheumatoid arthritis - tocilizumab</a>	replaced by TA247	
TA199	<a href="#">Psoriatic arthritis - etanercept, infliximab and adalimumab (TA199)</a>	Y	Chapter 10
TA200	<a href="#">Hepatitis C - peginterferon alfa and ribavirin (TA200)</a>	Y	No infections chapter
TA201	<a href="#">Asthma (in children) - omalizumab</a>	replaced by TA278	
TA202	<a href="#">Chronic lymphocytic leukaemia - ofatumumab</a>	Negative recommendation	
TA203	<a href="#">Diabetes (type 2) - liraglutide (TA203)</a>	replaced by NG28	
TA204	<a href="#">Osteoporotic fractures - denosumab (TA204)</a>	replaced by CG175	
TA205	<a href="#">Thrombocytopenic purpura - eltrombopag (TA205)</a>	replaced by TA293	
TA206	<a href="#">Lymphoma (non-Hodgkin's) - bendamustine (terminated appraisal)</a>	Terminated	
TA207	<a href="#">Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)</a>	Terminated	
TA208	<a href="#">Gastric cancer (HER2-positive metastatic) - trastuzumab</a>	Y	No chapter 8
TA209	<a href="#">Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib</a>	Negative recommendation	
TA210	<a href="#">Vascular disease - clopidogrel and dipyridamole (TA210)</a>	Y	Chapter 2
TA211	<a href="#">Constipation (women) - prucalopride (TA211)</a>	Y	Chapter 1
TA212	<a href="#">Colorectal cancer (metastatic) - bevacizumab</a>	Negative recommendation	
TA213	<a href="#">Schizophrenia - aripiprazole (TA213)</a>	Y	Chapter 4
TA214	<a href="#">Breast cancer - bevacizumab (in combination with a taxane)</a>	Negative recommendation	
TA215	<a href="#">Renal cell carcinoma (first line metastatic) - pazopanib</a>	Y	No chapter 8
TA216	<a href="#">Leukaemia (lymphocytic) - bendamustine</a>	Y	No chapter 8
TA217	<a href="#">Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (TA217)</a>	Y	Chapter 4
TA218	<a href="#">Myelodysplastic syndromes - azacitidine</a>	Y	No chapter 8
TA219	<a href="#">Everolimus for the second-line treatment of advanced renal cell carcinoma</a>	Negative recommendation	
TA220	<a href="#">Psoriatic arthritis - golimumab (TA220)</a>	Y	Chapter 10
TA221	<a href="#">Thrombocytopenic purpura - romiplostim (TA221)</a>	Y	No chapter 9
TA223	<a href="#">Peripheral arterial disease - cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate (TA223)</a>	Y	Chapter 2
TA224	<a href="#">Rheumatoid arthritis (methotrexate-naïve) - golimumab (terminated appraisal)</a>	Terminated	
TA225	<a href="#">Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab (TA225)</a>	Y	Chapter 10

TA226	<a href="#">Lymphoma (follicular non-Hodgkin's) - rituximab</a>	Y	No chapter 8
TA227	<a href="#">Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)</a>	Negative recommendation	
TA228	<a href="#">Multiple myeloma (first line) - bortezomib and thalidomide</a>	Y	No chapter 8
TA229	<a href="#">Macular oedema (retinal vein occlusion) - dexamethasone (TA229)</a>	Y	Chapter 11
TA230	<a href="#">Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)</a>	Y	Chapter 2
TA231	<a href="#">Depression - agomelatine (terminated appraisal)</a>	Terminated	
TA232	<a href="#">Epilepsy (partial) - retigabine (adjuvant) (TA232)</a>	Y	Chapter 4
TA233	<a href="#">Ankylosing spondylitis - golimumab (TA233)</a>	Replaced by TA383	
TA234	<a href="#">Rheumatoid arthritis - abatacept (2nd line) (TA234)</a>	Replaced by TA280	
TA235	<a href="#">Osteosarcoma - mifamurtide</a>	Y	No chapter 8
TA236	<a href="#">Acute coronary syndromes - ticagrelor (TA236)</a>	Y	Chapter 2
TA237	<a href="#">Macular oedema (diabetic) - ranibizumab (TA237)</a>	Replaced by TA274	
TA238	<a href="#">Arthritis (juvenile idiopathic, systemic) - tocilizumab</a>	Y	Chapter 10
TA239	<a href="#">Breast cancer (metastatic) - fulvestrant</a>	Negative recommendation	
TA240	<a href="#">Colorectal cancer (metastatic) - panitumumab (terminated appraisal)</a>	Terminated	
TA241	<a href="#">Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant)</a>	Negative recommendation	
TA242	<a href="#">Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)</a>	Negative recommendation	
TA243	<a href="#">Follicular lymphoma - rituximab (review)</a>	Y	No chapter 8
TA244	<a href="#">Chronic obstructive pulmonary disease - roflumilast (TA244)</a>	Negative recommendation	
TA245	<a href="#">Venous thromboembolism - apixaban (hip and knee surgery) (TA245)</a>	Y	Chapter 2
TA246	<a href="#">Venom anaphylaxis - immunotherapy pharmlagen</a>	Y	Chapter 3
TA247	<a href="#">Rheumatoid arthritis - tocilizumab (rapid review TA198) (TA247)</a>	Y	Chapter 10
TA248	<a href="#">Diabetes (type 2) - exenatide (prolonged release) (TA248)</a>	replaced by NG28	
TA249	<a href="#">Atrial fibrillation - dabigatran etexilate (TA249)</a>	Y	Chapter 2
TA250	<a href="#">Breast cancer (advanced) - eribulin</a>	Negative recommendation	
TA251	<a href="#">Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib</a>	Y	No chapter 8
TA252	<a href="#">Hepatitis C (genotype 1) - telaprevir (TA252)</a>	Y	No infections chapter
TA253	<a href="#">Hepatitis C (genotype 1) - boceprevir (TA253)</a>	Y	No infections chapter
TA254	<a href="#">Multiple sclerosis (relapsing-remitting) - fingolimod (TA254)</a>	Y	No chapter 8
TA255	<a href="#">Prostate cancer - cabazitaxel</a>	Negative recommendation	
TA256	<a href="#">Atrial fibrillation (stroke prevention) - rivaroxaban (TA256)</a>	Y	Chapter 2
TA257	<a href="#">Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor)</a>	Negative recommendation	
TA258	<a href="#">Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)</a>	Y	No chapter 8
TA259	<a href="#">Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen</a>	Y	No chapter 8
TA260	<a href="#">Migraine (chronic) - botulinum toxin type A</a>	Y	Chapter 4
TA261	<a href="#">Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban</a>	Y	Chapter 2
TA262	<a href="#">Ulcerative colitis (moderate to severe, second line) - adalimumab (terminated appraisal)</a>	Terminated	
TA263	<a href="#">Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer</a>	Negative recommendation	
TA264	<a href="#">Stroke (acute, ischaemic) - alteplase</a>	Y	Chapter 2
TA265	<a href="#">Bone metastases from solid tumours - denosumab</a>	Y	Chapter 6
TA267	<a href="#">Chronic heart failure - ivabradine</a>	Y	Chapter 2
TA266	<a href="#">Cystic fibrosis - mannitol dry powder for inhalation</a>	Y	Chapter 3
TA270	<a href="#">Leukaemia (acute myeloid) - decitabine (terminated appraisal)</a>	Terminated	
TA269	<a href="#">Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib</a>	Y	No chapter 8
TA268	<a href="#">Melanoma (stage III or IV) - ipilimumab</a>	Y	No chapter 8

TA271	<a href="#">Diabetic macular oedema - fluocinolone acetonide intravitreal implant</a>	Negative recommendation	
TA273	<a href="#">Hyperplasia (benign prostatic) - tadalafil (terminated appraisal)</a>	Terminated	
TA272	<a href="#">Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine</a>	Negative recommendation	
TA274	<a href="#">Macular oedema (diabetic) - ranibizumab</a>	Y	Chapter 11
TA275	<a href="#">Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban</a>	Y	Chapter 2
TA276	<a href="#">Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin</a>	Y	No infections chapter
TA277	<a href="#">Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal)</a>	Terminated	
TA278	<a href="#">Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201)</a>	Y	Chapter 3
TA281	<a href="#">Gout - canakinumab (terminated appraisal)</a>	Terminated	
TA282	<a href="#">Idiopathic pulmonary fibrosis - pirfenidone</a>	Replaced by TA504	
TA280	<a href="#">Rheumatoid arthritis - abatacept (2nd line) (rapid review of TA234)</a>	Replaced by TA375	
TA279	<a href="#">Vertebral fractures - vertebroplasty and kyphoplasty</a>	Not drug related	
TA284	<a href="#">Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer</a>	Negative recommendation	
TA283	<a href="#">Macular oedema (retinal vein occlusion) - ranibizumab</a>	Y	Chapter 11
TA285	<a href="#">Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab</a>	Negative recommendation	
TA286	<a href="#">Schizophrenia or bipolar disorder - loxapine inhalation (terminated appraisal)</a>	Terminated	
TA291	<a href="#">Gout (tophaceous, severe debilitating, chronic) - pegloticase</a>	Negative recommendation	
TA289	<a href="#">Myelofibrosis (splenomegaly, symptoms) - ruxolitinib</a>	Negative recommendation	
TA290	<a href="#">Overactive bladder - mirabegron</a>	Y	Chapter 7
TA287	<a href="#">Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban</a>	Y	Chapter 2
TA288	<a href="#">Type 2 diabetes - Dapagliflozin combination therapy</a>	Y	Chapter 6
TA292	<a href="#">Bipolar disorder (children) - aripiprazole</a>	Y	Chapter 4
TA293	<a href="#">Thrombocytopenic purpura - eltrombopag</a>	Y	No chapter 9
TA294	<a href="#">Macular degeneration (wet age-related) - aflibercept (1st line)</a>	Y	Chapter 11
TA295	<a href="#">Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor)</a>	Negative recommendation	
TA296	<a href="#">Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib</a>	Negative recommendation	
TA297	<a href="#">Vitreomacular traction - ocriplasmin</a>	Y	Chapter 11
TA298	<a href="#">Choroidal neovascularisation (pathological myopia) - ranibizumab</a>	Y	Chapter 11
TA301	<a href="#">Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271)</a>	Y	Chapter 11
TA300	<a href="#">Hepatitis C (children and young people) - peginterferon alfa and ribavirin</a>	Y	No infections chapter
TA302	<a href="#">Juvenile idiopathic arthritis (systemic) - canakinumab (terminated appraisal)</a>	Terminated	
TA299	<a href="#">Leukaemia (chronic myeloid) - bosutinib</a>	Negative recommendation	
TA303	<a href="#">Multiple sclerosis (relapsing) - teriflunomide</a>	Y	No chapter 8
TA304	<a href="#">Arthritis of the hip (end stage) - hip replacement (total) and resurfacing arthroplasty (Rev TA2, TA44)</a>	Not drug related	
TA305	<a href="#">Macular oedema (central retinal vein occlusion) - aflibercept solution for injection</a>	Y	Chapter 11
TA306	<a href="#">Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy</a>	Y	No chapter 8
TA307	<a href="#">Colorectal cancer (metastatic) - aflibercept</a>		
TA308	<a href="#">Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids)</a>	Y	Chapter 10
TA309	<a href="#">Lung cancer (non small cell, non squamous) - pemetrexed</a>	Negative recommendation	
TA310	<a href="#">Lung cancer (non small cell, EGFR mutation positive) - afatinib</a>	Y	No chapter 8
TA311	<a href="#">Multiple myeloma - bortezomib (induction therapy)</a>	Y	No chapter 8
TA312	<a href="#">Alemtuzumab for treating relapsing-remitting multiple sclerosis (TA312)</a>	Y	No chapter 8



TA313	<a href="#">Ustekinumab for treating active psoriatic arthritis (TA313)</a>	Negative recommendation	
TA314	<a href="#">Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (review of TA95 and TA120) (TA314)</a>	Not drug related	
TA315	<a href="#">Canagliflozin in combination therapy for treating type 2 diabetes (TA315)</a>	Y	Chapter 6
TA316	<a href="#">Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen (TA316)</a>	Y	No chapter 8
TA317	<a href="#">Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182)</a>	Y	Chapter 2
TA318	<a href="#">Lubiprostone for treating chronic idiopathic constipation</a>	Drug discontinued	
TA319	<a href="#">Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma</a>	Y	No chapter 8
TA320	<a href="#">Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (TA320)</a>	Y	No chapter 8
TA322	<a href="#">Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)</a>	Y	No chapter 8
TA321	<a href="#">Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA321)</a>	Y	No chapter 8
TA323	<a href="#">Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA142) (TA323)</a>	Y	No chapter 9
TA324	<a href="#">Dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (part review of technology appraisal guidance 88) (TA324)</a>	Not drug related	
TA325	<a href="#">Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)</a>	Y	Chapter 4
TA326	<a href="#">Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of NICE technology appraisal guidance 196) (TA326)</a>	Y	No chapter 8
TA327	<a href="#">Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA327)</a>	Y	Chapter 2
TA328	<a href="#">Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) (TA328)</a>	Terminated	
TA329	<a href="#">Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) (TA329)</a>	Y	Chapter 1
TA330	<a href="#">Sofosbuvir for treating chronic hepatitis C (TA330)</a>	Y	No infections chapter
TA331	<a href="#">Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C (TA331)</a>	Y	No infections chapter
TA332	<a href="#">Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer (TA332)</a>	Negative recommendation	
TA333	<a href="#">Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)</a>	Y	No chapter 8
TA334	<a href="#">Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (TA334)</a>	Terminated	
TA335	<a href="#">Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)</a>	Y	Chapter 2
TA336	<a href="#">Empagliflozin in combination therapy for treating type 2 diabetes (TA336)</a>	Y	Chapter 6
TA337	<a href="#">Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)</a>	Y	Chapter 1
TA338	<a href="#">Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib (TA338)</a>	Negative recommendation	
TA339	<a href="#">Omalizumab for previously treated chronic spontaneous urticaria (TA339)</a>	Y	Chapter 3
TA340	<a href="#">Ustekinumab for treating active psoriatic arthritis (rapid review of technology appraisal guidance 313) (TA340)</a>	Y	Chapter 10
TA341	<a href="#">Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)</a>	Y	Chapter 2
TA342	<a href="#">Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)</a>	Y	Chapter 1
TA343	<a href="#">Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)</a>	Y	No chapter 8
TA344	<a href="#">Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (TA344)</a>	Y	No chapter 8
TA346	<a href="#">Aflibercept for treating diabetic macular oedema (TA346)</a>	Y	Chapter 11
TA351	<a href="#">Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy (terminated appraisal) (TA351)</a>	Terminated	

TA349	<a href="#">Dexamethasone intravitreal implant for treating diabetic macular oedema (TA349)</a>	Y	Chapter 11
TA348	<a href="#">Everolimus for preventing organ rejection in liver transplantation (TA348)</a>	Negative recommendation	
TA345	<a href="#">Naloxegol for treating opioid-induced constipation (TA345)</a>	Y	Chapter 1
TA347	<a href="#">Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer (TA347)</a>	Y	No chapter 8
TA350	<a href="#">Secukinumab for treating moderate to severe plaque psoriasis (TA350)</a>	Y	Chapter 13
TA353	<a href="#">Bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) (TA353)</a>	Terminated	
TA354	<a href="#">Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)</a>	Y	Chapter 2
TA352	<a href="#">Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)</a>	Y	Chapter 1
TA355	<a href="#">Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355)</a>	Y	Chapter 2
TA356	<a href="#">Ruxolitinib for treating polycythaemia vera (terminated appraisal) (TA356)</a>	Terminated	
TA357	<a href="#">Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)</a>	Y	No chapter 8
TA358	<a href="#">Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)</a>	Y	Chapter 6
TA359	<a href="#">Idelalisib for treating chronic lymphocytic leukaemia (TA359)</a>	Y	No chapter 8
TA360	<a href="#">Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer (TA360)</a>	Negative recommendation	
TA361	<a href="#">Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal) (TA361)</a>	Terminated	
TA362	<a href="#">Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) (TA362)</a>	Terminated	
TA363	<a href="#">Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)</a>	Y	No infections chapter
TA364	<a href="#">Daclatasvir for treating chronic hepatitis C (TA364)</a>	Y	No infections chapter
TA365	<a href="#">Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)</a>	Y	No infections chapter
TA366	<a href="#">Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)</a>	Y	No chapter 8
TA367	<a href="#">Vortioxetine for treating major depressive episodes (TA367)</a>	Y	Chapter 4
TA368	<a href="#">Apremilast for treating moderate to severe plaque psoriasis (TA368)</a>	Negative recommendation	
TA369	<a href="#">Cyclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369)</a>	Y	Chapter 11
TA370	<a href="#">Bortezomib for previously untreated mantle cell lymphoma (TA370)</a>	Y	No chapter 8
TA371	<a href="#">Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane (TA371)</a>	Negative recommendation	
TA372	<a href="#">Apremilast for treating active psoriatic arthritis (TA372)</a>	Negative recommendation	
TA373	<a href="#">Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)</a>	Y	Chapter 10
TA374	<a href="#">Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)</a>	Y	No chapter 8
HST1	<a href="#">Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)</a>	Y	No Chapter 9
HST2	<a href="#">Elosulfase alfa for treating mucopolysaccharidosis type IVa (HST2)</a>	Y	No Chapter 9
TA375	<a href="#">Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)</a>	Y	Chapter 10
TA376	<a href="#">Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA376)</a>	Y	No Chapter 8
TA377	<a href="#">Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)</a>	Y	No Chapter 8
TA378	<a href="#">Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)</a>	Negative recommendation	



TA379	<a href="#">Nintedanib for treating idiopathic pulmonary fibrosis (TA379)</a>	Y	Chapter 3
TA380	<a href="#">Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)</a>	Y	No Chapter 8
TA381	<a href="#">Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (TA381)</a>	Y	No Chapter 8
TA382	<a href="#">Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) (TA382)</a>	Terminated	
TA383	<a href="#">TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)</a>	Y	Chapter 10
TA384	<a href="#">Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)</a>	Y	No Chapter 8
TA385	<a href="#">Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)</a>	Y	Chapter 2
TA386	<a href="#">Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)</a>	Y	No Chapter 8
TA387	<a href="#">Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated</a>	Y	No Chapter 8
TA388	<a href="#">Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction</a>	Y	Chapter 2
TA389	<a href="#">Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer</a>	Y	No Chapter 8
TA390	<a href="#">Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes</a>	Y	Chapter 6
TA391	<a href="#">Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel</a>	Y	No Chapter 8
TA392	<a href="#">Adalimumab for treating moderate to severe hidradenitis suppurativa</a>	Y	Chapter 13
TA393	<a href="#">Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia</a>	Y	Chapter 2
TA394	<a href="#">Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia</a>	Y	Chapter 2
TA395	<a href="#">Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer</a>	Y	No Chapter 8
TA396	<a href="#">Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma</a>	Y	No Chapter 8
TA397	<a href="#">Belimumab for treating active autoantibody-positive systemic lupus erythematosus</a>	Replaced by NICE TA397	
TA398	<a href="#">Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation</a>	Negative recommendation	
TA399	<a href="#">Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts</a>	Negative recommendation	
TA400	<a href="#">Nivolumab in combination with ipilimumab for treating advanced melanoma</a>	Y	No Chapter 8
HST3	<a href="#">Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene</a>	Y	Chapter 10
TA401	<a href="#">Bosutinib for previously treated chronic myeloid leukaemia</a>	Y	No Chapter 8
TA402	<a href="#">Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin</a>	Y	No Chapter 8
TA403	<a href="#">Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer</a>	Negative recommendation	
TA404	<a href="#">Degarelix for treating advanced hormone-dependent prostate cancer</a>	Y	Chapter 8
TA405	<a href="#">Trifluridine–tipiracil for previously treated metastatic colorectal cancer</a>	Y	No Chapter 8
TA406	<a href="#">Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer</a>	Y	No Chapter 8
TA407	<a href="#">Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors</a>	Y	Chapter 10
TA408	<a href="#">Pegaspargase for treating acute lymphoblastic leukaemia</a>	Y	No Chapter 8
TA409	<a href="#">Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion</a>	Y	Chapter 11
TA410	<a href="#">Talimogene laherparepvec for treating unresectable metastatic melanoma</a>	Y	No Chapter 8

TA411	<a href="#">Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer</a>	Negative recommendation	
TA412	<a href="#">Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases</a>	Not drug related	
TA413	<a href="#">Elbasvir–grazoprevir for treating chronic hepatitis C</a>	Y	No infections chapter
TA414	<a href="#">Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma</a>	Negative recommendation	
TA415	<a href="#">Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor</a>	Y	Chapter 10
TA416	<a href="#">Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer</a>	Y	No chapter 8
TA417	<a href="#">Nivolumab for previously treated advanced renal cell carcinoma</a>	Y	No chapter 8
TA418	<a href="#">Dapagliflozin in triple therapy for treating type 2 diabetes</a>	Y	Chapter 6
TA419	<a href="#">Apremilast for treating moderate to severe plaque psoriasis</a>	Y	Chapter 13
TA420	<a href="#">Ticagrelor for preventing atherothrombotic events after myocardial infarction</a>	Y	Chapter 2
TA421	<a href="#">Everolimus with exemestane for treating advanced breast cancer after endocrine therapy</a>	Y	No Chapter 8
TA422	<a href="#">Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer</a>	Y	No Chapter 8
TA423	<a href="#">Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens</a>	Y	No Chapter 8
TA424	<a href="#">Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer</a>	Y	No Chapter 8
TA425	<a href="#">Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia</a>	Y	No Chapter 8
TA426	<a href="#">Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia</a>	Y	No Chapter 8
TA427	<a href="#">Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib</a>	Y	No Chapter 8
TA428	<a href="#">Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy</a>	Y	No Chapter 8
TA429	<a href="#">Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation</a>	Y	No Chapter 8
TA430	<a href="#">Sofosbuvir–velpatasvir for treating chronic hepatitis C</a>	Y	No infections chapter
TA431	<a href="#">Mepolizumab for treating severe refractory eosinophilic asthma</a>	Replaced by NICE TA671	
TA432	<a href="#">Everolimus for advanced renal cell carcinoma after previous treatment</a>	Y	No Chapter 8
HST4	<a href="#">Migalastat for treating Fabry disease</a>	Y	No Chapter 9
TA433	<a href="#">Apremilast for treating active psoriatic arthritis</a>	Y	Chapter 10
TA434	<a href="#">Elotuzumab for previously treated multiple myeloma (terminated appraisal)</a>	Terminated	
TA435	<a href="#">Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal)</a>	Terminated	
TA436	<a href="#">Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)</a>	Terminated	
TA437	<a href="#">Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)</a>	Terminated	
TA438	<a href="#">Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)</a>	Terminated	
TA439	<a href="#">Cetuximab and panitumumab for previously untreated metastatic colorectal cancer</a>	Y	No Chapter 8
TA440	<a href="#">Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine</a>	Negative recommendation	
TA441	<a href="#">Daclizumab for treating relapsing–remitting multiple sclerosis</a>	Y	No Chapter 8
TA442	<a href="#">Ixekizumab for treating moderate to severe plaque psoriasis</a>	Y	Chapter 13

TA443	<a href="#">Obeticholic acid for treating primary biliary cholangitis</a>	Y	Chapter 1
TA444	<a href="#">Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)</a>	Terminated	
TA445	<a href="#">Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs</a>	Y	Chapter 10
TA446	<a href="#">Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma</a>	Y	No Chapter 8
TA447	<a href="#">Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer</a>	Y	No Chapter 8
TA448	<a href="#">Etelcalcetide for treating secondary hyperparathyroidism</a>	Y	No Chapter 9
TA449	<a href="#">Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease</a>	Y	No Chapter 8
TA450	<a href="#">Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia</a>	Y	No Chapter 8
TA451	<a href="#">Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia</a>	Y	No Chapter 8
HST5	<a href="#">Eliglustat for treating type 1 Gaucher disease</a>	Y	No Chapter 9
TA452	<a href="#">Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)</a>	Terminated	
TA453	<a href="#">Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal)</a>	Terminated	
TA454	<a href="#">Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)</a>	Terminated	
TA455	<a href="#">Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people</a>	Y	Chapter 13
TA456	<a href="#">Ustekinumab for moderately to severely active Crohn's disease after previous treatment</a>	Y	Chapter 1
TA457	<a href="#">Carfilzomib for previously treated multiple myeloma</a>	Y	No Chapter 8
TA458	<a href="#">Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane</a>	Y	No Chapter 8
TA459	<a href="#">Collagenase clostridium histolyticum for treating Dupuytren's contracture</a>	Y	Chapter 10
TA460	<a href="#">Adalimumab and dexamethasone for treating non-infectious uveitis</a>	Y	Chapter 11
TA461	<a href="#">Roflumilast for treating chronic obstructive pulmonary disease</a>	Y	Chapter 3
TA462	<a href="#">Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma</a>	Y	No Chapter 8
TA463	<a href="#">Cabozantinib for previously treated advanced renal cell carcinoma</a>	Y	No Chapter 8
TA464	<a href="#">Bisphosphonates for treating osteoporosis</a>	Y	Chapter 6
TA465	<a href="#">Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma</a>	Y	No Chapter 8
TA466	<a href="#">Baricitinib for moderate to severe rheumatoid arthritis</a>	Y	Chapter 10
TA467	<a href="#">Holoclar for treating limbal stem cell deficiency after eye burns</a>	Y	Chapter 11
HST6	<a href="#">Asfotase alfa for treating paediatric-onset hypophosphatasia</a>	Y	No Chapter 9
TA468	<a href="#">Methylalntrexone bromide for treating opioid-induced constipation (terminated appraisal)</a>	Terminated	
TA469	<a href="#">Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal)</a>	Terminated	
TA470	<a href="#">Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal)</a>	Terminated	
TA471	<a href="#">Eluxadoline for treating irritable bowel syndrome with diarrhoea</a>	Y	Chapter 1
TA472	<a href="#">Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab</a>	Y	No Chapter 8
TA473	<a href="#">Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck</a>	Y	No Chapter 8

TA474	<a href="#">Sorafenib for treating advanced hepatocellular carcinoma</a>	Y	No Chapter 8
TA475	<a href="#">Dimethyl fumarate for treating moderate to severe plaque psoriasis</a>	Y	Chapter 13
TA476	<a href="#">Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer</a>	Y	No Chapter 8
TA477	<a href="#">Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee</a>	Not drug related	
TA478	<a href="#">Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma</a>	Y	No Chapter 8
TA479	<a href="#">Reslizumab for treating severe eosinophilic asthma</a>	Y	Chapter 3
TA480	<a href="#">Tofacitinib for moderate to severe rheumatoid arthritis</a>	Y	Chapter 10
TA481	<a href="#">Immunosuppressive therapy for kidney transplant in adults</a>	Y	No Chapter 8
TA482	<a href="#">Immunosuppressive therapy for kidney transplant in children and young people</a>	Y	No Chapter 8
TA483	<a href="#">Nivolumab for previously treated squamous non-small-cell lung cancer</a>	Y	No Chapter 8
TA484	<a href="#">Nivolumab for previously treated non-squamous non-small-cell lung cancer</a>	Y	No Chapter 8
TA485	<a href="#">Sarilumab for moderate to severe rheumatoid arthritis</a>	Y	Chapter 10
TA486	<a href="#">Aflibercept for treating choroidal neovascularisation</a>	Y	Chapter 11
TA487	<a href="#">Venetoclax for treating chronic lymphocytic leukaemia</a>	Y	No Chapter 8
TA488	<a href="#">Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours</a>	Y	No Chapter 8
TA489	<a href="#">Vismodegib for treating basal cell carcinoma</a>	Negative recommendation	
TA490	<a href="#">Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy</a>	Y	No Chapter 8
TA491	<a href="#">Ibrutinib for treating Waldenstrom's macroglobulinaemia</a>	Y	No Chapter 8
TA492	<a href="#">Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable</a>	Y	No Chapter 8
TA493	<a href="#">Cladribine tablets for treating relapsing–remitting multiple sclerosis</a>	Y	No Chapter 8
TA494	<a href="#">Naltrexone–bupropion for managing overweight and obesity</a>	Negative recommendation	
TA495	<a href="#">Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer</a>	Y	No Chapter 8
TA496	<a href="#">Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer</a>	Y	No Chapter 8
TA497	<a href="#">Golimumab for treating non-radiographic axial spondyloarthritis</a>	Y	Chapter 10
TA498	<a href="#">Lenvatinib with everolimus for previously treated advanced renal cell carcinoma</a>	Y	No Chapter 8
TA499	<a href="#">Glecaprevir–pibrentasvir for treating chronic hepatitis C</a>	Y	No infections chapter
TA500	<a href="#">Ceritinib for untreated ALK-positive non-small-cell lung cancer</a>	Y	No Chapter 8
TA501	<a href="#">Intrabeam radiotherapy system for adjuvant treatment of early breast cancer</a>	Not drug related	
TA502	<a href="#">Ibrutinib for treating relapsed or refractory mantle cell lymphoma</a>	Y	No Chapter 8
TA503	<a href="#">Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer</a>	Negative recommendation	
HST7	<a href="#">Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency</a>	Y	No appropriate chapter
TA504	<a href="#">Pirfenidone for treating idiopathic pulmonary fibrosis</a>	Y	Chapter 3
TA505	<a href="#">Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma</a>	Y	No Chapter 8

TA506	<a href="#">Lesinurad for treating chronic hyperuricaemia in people with gout</a>	Negative recommendation	
TA507	<a href="#">Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C</a>	Y	No infections chapter
TA508	<a href="#">Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee</a>	Not drug related	
TA509	<a href="#">Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer</a>	Y	No Chapter 8
TA510	<a href="#">Daratumumab monotherapy for treating relapsed and refractory multiple myeloma</a>	Y	No Chapter 8
TA511	<a href="#">Brodalumab for treating moderate to severe plaque psoriasis</a>	Y	Chapter 13
TA512	<a href="#">Tivozanib for treating advanced renal cell carcinoma</a>	Y	No Chapter 8
TA513	<a href="#">Obinutuzumab for untreated advanced follicular lymphoma</a>	Y	No Chapter 8
TA514	<a href="#">Regorafenib for previously treated advanced hepatocellular carcinoma</a>	Negative recommendation	
TA515	<a href="#">Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen</a>	Negative recommendation	
TA516	<a href="#">Cabozantinib for treating medullary thyroid cancer</a>	Y	No Chapter 8
TA517	<a href="#">Avelumab for treating metastatic Merkel cell carcinoma</a>	Y	No Chapter 8
TA518	<a href="#">Tocilizumab for treating giant cell arteritis</a>	Y	Chapter 10
TA519	<a href="#">Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy</a>	Y	No Chapter 8
TA520	<a href="#">Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy</a>	Y	No Chapter 8
TA521	<a href="#">Guselkumab for treating moderate to severe plaque psoriasis</a>	Y	Chapter 13
TA522	<a href="#">Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable</a>	Y	No Chapter 8
TA523	<a href="#">Midostaurin for untreated acute myeloid leukaemia</a>	Y	No Chapter 8
TA524	<a href="#">Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma</a>	Y	No Chapter 8
TA525	<a href="#">Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy</a>	Y	No Chapter 8
TA526	<a href="#">Arsenic trioxide for treating acute promyelocytic leukaemia</a>	Y	No Chapter 8
TA527	<a href="#">Beta interferons and glatiramer acetate for treating multiple sclerosis</a>	Y	No Chapter 8
TA528	<a href="#">Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer</a>	Y	No Chapter 8
TA529	<a href="#">Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer</a>	Y	No Chapter 8
TA530	<a href="#">Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy</a>	Negative recommendation	
TA531	<a href="#">Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer</a>	Y	No Chapter 8
TA532	<a href="#">Cenegelein for treating neurotrophic keratitis</a>	Negative recommendation	
TA533	<a href="#">Ocrelizumab for treating relapsing–remitting multiple sclerosis</a>	Y	No Chapter 8
TA534	<a href="#">Dupilumab for treating moderate to severe atopic dermatitis</a>	Y	Chapter 13
TA535	<a href="#">Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine</a>	Y	No Chapter 8
TA536	<a href="#">Alectinib for untreated ALK-positive advanced non-small-cell lung cancer</a>	Y	No Chapter 8
TA537	<a href="#">Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs</a>	Y	Chapter 10
TA538	<a href="#">Dinutuximab beta for treating neuroblastoma</a>	Y	No Chapter 8

TA539	<a href="#">Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours</a>	Y	No Chapter 8
TA540	<a href="#">Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma</a>	Y	No Chapter 8
TA541	<a href="#">Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia</a>	Y	No Chapter 8
TA542	<a href="#">Cabozantinib for untreated advanced renal cell carcinoma</a>	Y	No Chapter 8
TA543	<a href="#">Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs</a>	Y	Chapter 10
HST8	<a href="#">Burosumab for treating X-linked hypophosphataemia in children and young people</a>	Y	No appropriate chapter
TA544	<a href="#">Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma</a>	Y	No Chapter 8
TA545	<a href="#">Gemtuzumab ozogamicin for untreated acute myeloid leukaemia</a>	Y	No Chapter 8
TA546	<a href="#">Padeliporfin for untreated localised prostate cancer</a>	Negative recommendation	
TA547	<a href="#">Tofacitinib for moderately to severely active ulcerative colitis</a>	Y	Chapter 1
TA548	<a href="#">Decitabine for untreated acute myeloid leukaemia (terminated appraisal)</a>	Terminated	
TA549	<a href="#">Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal)</a>	Terminated	
TA550	<a href="#">Vandetanib for treating medullary thyroid cancer</a>	Negative recommendation	
TA551	<a href="#">Lenvatinib for untreated advanced hepatocellular carcinoma</a>	Y	No Chapter 8
TA552	<a href="#">Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia</a>	Y	No Chapter 8
TA553	<a href="#">Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence</a>	Y	No Chapter 8
TA554	<a href="#">Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years</a>	Y	No Chapter 8
TA555	<a href="#">Regorafenib for previously treated advanced hepatocellular carcinoma</a>	Y	No Chapter 8
TA556	<a href="#">Darvadstrocel for treating complex perianal fistulas in Crohn's disease</a>	Negative recommendation	
TA557	<a href="#">Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer</a>	Y	No Chapter 8
TA558	<a href="#">Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease</a>	Y	No Chapter 8
TA559	<a href="#">Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies</a>	Y	No Chapter 8
TA560	<a href="#">Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)</a>	Terminated	
TA561	<a href="#">Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia</a>	Y	No Chapter 8
TA562	<a href="#">Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma</a>	Y	No Chapter 8
TA563	<a href="#">Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer</a>	Y	No Chapter 8
TA564	<a href="#">Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal)</a>	Terminated	
TA565	<a href="#">Benralizumab for treating severe eosinophilic asthma</a>	Y	Chapter 3
TA566	<a href="#">Cochlear implants for children and adults with severe to profound deafness</a>	Not drug related	
TA567	<a href="#">Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies</a>	Y	No Chapter 8
TA568	<a href="#">Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal)</a>	Terminated	
TA569	<a href="#">Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer</a>	Y	No Chapter 8
TA570	<a href="#">Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal)</a>	Terminated	



TA571	<a href="#">Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib</a>	Y	No Chapter 8
TA572	<a href="#">Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes</a>	Y	Chapter 6
TA573	<a href="#">Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma</a>	Y	No Chapter 8
TA574	<a href="#">Certolizumab pegol for treating moderate to severe plaque psoriasis</a>	Y	Chapter 13
TA575	<a href="#">Tildrakizumab for treating moderate to severe plaque psoriasis</a>	Y	Chapter 13
TA576	<a href="#">Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal)</a>	Terminated	
TA577	<a href="#">Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma</a>	Y	No Chapter 8
TA578	<a href="#">Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation</a>	Y	No Chapter 8
TA579	<a href="#">Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy</a>	Y	No Chapter 8
TA580	<a href="#">Enzalutamide for hormone-relapsed non-metastatic prostate cancer</a>	Negative recommendation	
TA581	<a href="#">Nivolumab with ipilimumab for untreated advanced renal cell carcinoma</a>	Y	No Chapter 8
TA582	<a href="#">Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal)</a>	Terminated	
HST9	<a href="#">Inotersen for treating hereditary transthyretin amyloidosis</a>	Y	No Chapter 9
TA583	<a href="#">Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes</a>	Y	Chapter 6
TA584	<a href="#">Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer</a>	Y	No Chapter 8
TA585	<a href="#">Ocrelizumab for treating primary progressive multiple sclerosis</a>	Y	No Chapter 8
TA586	<a href="#">Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib</a>	Y	No Chapter 8
TA587	<a href="#">Lenalidomide plus dexamethasone for previously untreated multiple myeloma</a>	Y	No Chapter 8
TA588	<a href="#">Nusinersen for treating spinal muscular atrophy</a>	Y	No Chapter 8
TA589	<a href="#">Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity</a>	Y	No Chapter 8
TA590	<a href="#">Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis</a>	Y	Chapter 11
TA591	<a href="#">Letermovir for preventing cytomegalovirus disease after a stem cell transplant</a>	Y	No Chapter 8
TA592	<a href="#">Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma</a>	Y	No Chapter 8
HST10	<a href="#">Patisiran for treating hereditary transthyretin amyloidosis</a>	Y	No Chapter 9
TA593	<a href="#">Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer</a>	Y	No Chapter 8
TA594	<a href="#">Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal)</a>	Terminated	
TA595	<a href="#">Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer</a>	Y	No Chapter 8
TA596	<a href="#">Risankizumab for treating moderate to severe plaque psoriasis</a>	Y	Chapter 13
TA597	<a href="#">Dapagliflozin with insulin for treating type 1 diabetes</a>	Y	Chapter 6
TA598	<a href="#">Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy</a>	Y	No Chapter 8
TA599	<a href="#">Sodium zirconium cyclosilicate for treating hyperkalaemia</a>	Y	No Chapter 9
TA600	<a href="#">Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer</a>	Y	No Chapter 8
TA601	<a href="#">Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal)</a>	Terminated	

TA602	<a href="#">Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)</a>	Terminated	
TA603	<a href="#">Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal)</a>	Terminated	
TA604	<a href="#">Idelalisib for treating refractory follicular lymphoma</a>	Negative recommendation	
TA605	<a href="#">Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea</a>	Y	Chapter 4
HST11	<a href="#">Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations</a>	Y	Chapter 11
TA606	<a href="#">Lanadelumab for preventing recurrent attacks of hereditary angioedema</a>	Y	Chapter 3
TA607	<a href="#">Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease</a>	Y	Chapter 2
TA608	<a href="#">Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal)</a>	Terminated	
TA609	<a href="#">Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal)</a>	Terminated	
TA610	<a href="#">Pentosan polysulfate sodium for treating bladder pain syndrome</a>	Y	Chapter 7
TA611	<a href="#">Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer</a>	Y	No Chapter 8
TA612	<a href="#">Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab</a>	Y	No Chapter 8
HST12	<a href="#">Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2</a>	Y	No Chapter 9
TA613	<a href="#">Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy</a>	Negative recommendation	
TA614	<a href="#">Cannabidiol with clobazam for treating seizures associated with Dravet syndrome</a>	Y	Chapter 4
TA615	<a href="#">Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome</a>	Y	Chapter 4
TA616	<a href="#">Cladribine for treating relapsing–remitting multiple sclerosis</a>	Y	No Chapter 8
TA617	<a href="#">Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure</a>	Y	No Chapter 9
TA618	<a href="#">Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)</a>	Terminated	
TA619	<a href="#">Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer</a>	Y	No Chapter 8
TA620	<a href="#">Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer</a>	Y	No Chapter 8
TA621	<a href="#">Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer</a>	Negative recommendation	
TA622	<a href="#">Sotagliflozin with insulin for treating type 1 diabetes</a>	Y	Chapter 6
TA623	<a href="#">Patiomer for treating hyperkalaemia</a>	Y	No Chapter 9
TA624	<a href="#">Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis</a>	Y	No Chapter 8
TA625	<a href="#">Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal)</a>	Terminated	
TA626	<a href="#">Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure</a>	Y	No Chapter 9
TA627	<a href="#">Lenalidomide with rituximab for previously treated follicular lymphoma</a>	Y	No Chapter 8
TA628	<a href="#">Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer</a>	Y	No Chapter 8
TA629	<a href="#">Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab</a>	Y	No Chapter 8
TA630	<a href="#">Larotrectinib for treating NTRK fusion-positive solid tumours</a>	Y	No Chapter 8
TA631	<a href="#">Fremanezumab for preventing migraine</a>	Y	Chapter 4
TA632	<a href="#">Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer</a>	Y	No Chapter 8

TA633	<a href="#">Ustekinumab for treating moderately to severely active ulcerative colitis</a>	Y	Chapter 1
TA634	<a href="#">Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)</a>	Terminated	
TA635	<a href="#">Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)</a>	Terminated	
TA636	<a href="#">Eculizumab for treating refractory myasthenia gravis (terminated appraisal)</a>	Terminated	
TA637	<a href="#">Ranibizumab for treating diabetic retinopathy (terminated appraisal)</a>	Terminated	
TA638	<a href="#">Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer</a>	Y	No Chapter 8
TA639	<a href="#">Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer</a>	Y	No Chapter 8
TA640	<a href="#">Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant</a>	Y	No Chapter 8
TA641	<a href="#">Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma</a>	Y	No Chapter 8
TA642	<a href="#">Gilteritinib for treating relapsed or refractory acute myeloid leukaemia</a>	Y	No Chapter 8
TA643	<a href="#">Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer</a>	Y	No Chapter 8
TA644	<a href="#">Entrectinib for treating NTRK fusion-positive solid tumours</a>	Y	No Chapter 8
TA645	<a href="#">Avelumab with axitinib for untreated advanced renal cell carcinoma</a>	Y	No Chapter 8
TA646	<a href="#">Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal)</a>	Terminated	
TA647	<a href="#">Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal)</a>	Terminated	
TA648	<a href="#">Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)</a>	Terminated	
TA649	<a href="#">Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma</a>	Y	No Chapter 8
TA650	<a href="#">Pembrolizumab with axitinib for untreated advanced renal cell carcinoma</a>	Negative recommendation	
TA651	<a href="#">Naldemedine for treating opioid-induced constipation</a>	Y	Chapter 1
TA652	<a href="#">Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal)</a>	Terminated	
TA653	<a href="#">Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer</a>	Y	No Chapter 8
TA654	<a href="#">Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer</a>	Y	No Chapter 8
HST13	<a href="#">Volanesorsen for treating familial chylomicronaemia syndrome</a>	Y	Chapter 2
TA655	<a href="#">Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy</a>	Y	No Chapter 8
TA656	<a href="#">Siponimod for treating secondary progressive multiple sclerosis</a>	Y	No Chapter 8
TA657	<a href="#">Carfilzomib for previously treated multiple myeloma</a>	Y	No Chapter 8
TA658	<a href="#">Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma</a>	Y	No Chapter 8
TA659	<a href="#">Galcanezumab for preventing migraine</a>	Y	Chapter 4
TA660	<a href="#">Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer</a>	Y	No Chapter 8
TA661	<a href="#">Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma</a>	Y	No Chapter 8
TA662	<a href="#">Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal)</a>	Terminated	
TA663	<a href="#">Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia</a>	Y	No Chapter 8
TA664	<a href="#">Liraglutide for managing overweight and obesity</a>	Y	Chapter 4

TA665	<a href="#">Upadacitinib for treating severe rheumatoid arthritis</a>	Y	Chapter 10
TA666	<a href="#">Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma</a>	Y	No Chapter 8
TA667	<a href="#">Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura</a>	Y	Chapter 9
TA668	<a href="#">Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer</a>	Y	No Chapter 8
TA669	<a href="#">Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies</a>	Negative recommendation	
TA670	<a href="#">Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor</a>	Y	No Chapter 8
TA671	<a href="#">Mepolizumab for treating severe eosinophilic asthma</a>	Y	Chapter 3
TA672	<a href="#">Brolucizumab for treating wet age-related macular degeneration</a>	Y	Chapter 11
TA673	<a href="#">Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy</a>	Y	No Chapter 8
TA674	<a href="#">Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)</a>	Terminated	
TA675	<a href="#">Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal)</a>	Terminated	
TA676	<a href="#">Filgotinib for treating moderate to severe rheumatoid arthritis</a>	Y	Chapter 10
HST14	<a href="#">Metreleptin for treating lipodystrophy</a>	Y	Chapter 6
TA677	<a href="#">Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma</a>	Y	No Chapter 8
TA678	<a href="#">Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)</a>	Terminated	
TA679	<a href="#">Dapagliflozin for treating chronic heart failure with reduced ejection fraction</a>	Y	Chapter 2
TA680	<a href="#">Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma</a>	Y	No Chapter 8
TA681	<a href="#">Baricitinib for treating moderate to severe atopic dermatitis</a>	Y	Chapter 13
TA682	<a href="#">Erenumab for preventing migraine</a>	Y	Chapter 4
TA683	<a href="#">Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer</a>	Y	No Chapter 8
TA684	<a href="#">Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease</a>	Y	No Chapter 8
TA685	<a href="#">Anakinra for treating Still's disease</a>	Y	Chapter 10
TA686	<a href="#">Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)</a>	Terminated	
TA687	<a href="#">Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy</a>	Y	No Chapter 8
TA688	<a href="#">Selective internal radiation therapies for treating hepatocellular carcinoma</a>	Y	No Chapter 8
TA689	<a href="#">Acalabrutinib for treating chronic lymphocytic leukaemia</a>	Y	No Chapter 8
TA690	<a href="#">Teduglutide for treating short bowel syndrome (terminated appraisal)</a>	Terminated	
TA691	<a href="#">Avelumab for untreated metastatic Merkel cell carcinoma</a>	Y	No Chapter 8
TA692	<a href="#">Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy</a>	Negative recommendation	
TA693	<a href="#">Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer</a>	Y	No Chapter 8
TA694	<a href="#">Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia</a>	Y	Chapter 2
TA695	<a href="#">Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma</a>	Y	No Chapter 8
TA696	<a href="#">Tafamidis for treating transthyretin amyloidosis with cardiomyopathy</a>	Negative recommendation	

TA697	<a href="#">Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban</a>	Y	Chapter 2
TA698	<a href="#">Ravulizumab for treating paroxysmal nocturnal haemoglobinuria</a>	Y	Chapter 9
TA699	<a href="#">Ofatumumab for treating relapsing multiple sclerosis</a>	Y	No Chapter 8
TA700	<a href="#">Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal)</a>	Terminated	
TA701	<a href="#">Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal)</a>	Terminated	
TA702	<a href="#">Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal)</a>	Terminated	
TA703	<a href="#">Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal)</a>	Terminated	
TA704	<a href="#">Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies</a>	Y	No Chapter 8
TA705	<a href="#">Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer</a>	Y	No Chapter 8
TA706	<a href="#">Ozanimod for treating relapsing–remitting multiple sclerosis</a>	Negative recommendation	
TA708	<a href="#">Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis</a>	Y	Chapter 1
TA709	<a href="#">Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency</a>	Y	No Chapter 8
TA710	<a href="#">Ravulizumab for treating atypical haemolytic uraemic syndrome</a>	Y	Chapter 9
TA711	<a href="#">Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs</a>	Y	Chapter 10
TA712	<a href="#">Enzalutamide for treating hormone-sensitive metastatic prostate cancer</a>	Y	Chapter 8
TA713	<a href="#">Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy</a>	Y	No Chapter 8
HST15	<a href="#">Onasemnogene abeparvovec for treating spinal muscular atrophy</a>	Y	Chapter 10
TA714	<a href="#">Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)</a>	Terminated	
TA715	<a href="#">Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed</a>	Y	Chapter 10
TA716	<a href="#">Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency</a>	Y	No Chapter 8
TA717	<a href="#">Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal)</a>	Terminated	
TA718	<a href="#">Ixekizumab for treating axial spondyloarthritis</a>	Y	Chapter 10
TA719	<a href="#">Secukinumab for treating non-radiographic axial spondyloarthritis</a>	Y	Chapter 10
TA720	<a href="#">Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma</a>	Y	No Chapter 8
TA721	<a href="#">Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer</a>	Y	Chapter 8
TA722	<a href="#">Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement</a>	Y	No Chapter 8
TA723	<a href="#">Bimekizumab for treating moderate to severe plaque psoriasis</a>	Y	Chapter 13
TA724	<a href="#">Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer</a>	Negative recommendation	
TA725	<a href="#">Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy</a>	Y	No Chapter 8
TA726	<a href="#">Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)</a>	Terminated	
TA727	<a href="#">Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)</a>	Terminated	
TA728	<a href="#">Midostaurin for treating advanced systemic mastocytosis</a>	Y	No Chapter 8
TA729	<a href="#">Sapropterin for treating hyperphenylalaninaemia in phenylketonuria</a>	Y	Chapter 9

TA730	<a href="#">Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal)</a>	Terminated	
TA731	<a href="#">Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal)</a>	Terminated	
TA732	<a href="#">Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal)</a>	Terminated	
TA733	<a href="#">Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia</a>	Y	Chapter 2
TA734	<a href="#">Secukinumab for treating moderate to severe plaque psoriasis in children and young people</a>	Y	Chapter 13
TA735	<a href="#">Tofacitinib for treating juvenile idiopathic arthritis</a>	Y	Chapter 10
TA736	<a href="#">Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy</a>	Y	No Chapter 8
TA737	<a href="#">Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer</a>	Y	No Chapter 8
TA738	<a href="#">Berotralstat for preventing recurrent attacks of hereditary angioedema</a>	Y	Chapter 3
TA739	<a href="#">Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable</a>	Y	No Chapter 8
TA740	<a href="#">Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer</a>	Y	Chapter 8
TA741	<a href="#">Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer</a>	Y	Chapter 8
TA742	<a href="#">Selpercatinib for treating advanced thyroid cancer with RET alterations</a>	Y	No Chapter 8
TA743	<a href="#">Crizanlizumab for preventing sickle cell crises in sickle cell disease</a>	Y	Chapter 9
TA744	<a href="#">Upadacitinib for treating moderate rheumatoid arthritis</a>	Y	Chapter 10
TA745	<a href="#">NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal)</a>	Terminated	
TA746	<a href="#">Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer</a>	Y	No Chapter 8
TA747	<a href="#">Nintedanib for treating progressive fibrosing interstitial lung diseases</a>	Y	No Chapter 8
TA748	<a href="#">Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders</a>	Y	Chapter 4
HST16	<a href="#">Givosiran for treating acute hepatic porphyria</a>	Y	Chapter 9
TA749	<a href="#">Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal)</a>	Terminated	
TA750	<a href="#">Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal)</a>	Terminated	
TA751	<a href="#">Dupilumab for treating severe asthma with type 2 inflammation</a>	Y	Chapter 3
TA752	<a href="#">Belimumab for treating active autoantibody-positive systemic lupus erythematosus</a>	Y	Chapter 10
TA753	<a href="#">Cenobamate for treating focal onset seizures in epilepsy</a>	Y	Chapter 4
TA754	<a href="#">Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome</a>	Y	No Chapter 8
TA755	<a href="#">Risdiplam for treating spinal muscular atrophy</a>	Y	Chapter 10
TA756	<a href="#">Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis</a>	Y	No Chapter 8

Up-to-date on 01/01/2022